RESUMO
Zoledronate (ZOL) inhibits farnesyl pyrophosphate synthase leading to intracellular accumulation of isopentenyl pyrophosphate/triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester (IPP/ApppI). Cytotoxic Vγ9Vδ2 T cells have been shown to recognize IPP/ApppI in breast cancer cells. Further, human breast cancer cells have been shown to differ remarkably in their ZOL treatment induced IPP/ApppI production and responses to that. In this communication we analysed the responsiveness of prostate cancer cells PC-3 and DU-145, Caki-2 renal carcinoma cells and U87MG glioblastoma cells to ZOL treatment, and the subsequent activation of Vγ9Vδ2 T-cell cytotoxicity. Of the cell lines tested, PC-3 cells were not susceptible to Vγ9Vδ2 T-cell cytotoxicity due to low activity of the mevalonate pathway and low amount of IPP formed. However, the resistance of PC-3 cells to Vγ9Vδ2 T-cell cytotoxicity could be abrogated by upregulation of the mevalonate pathway through cholesterol depletion.
Assuntos
Colesterol/deficiência , Difosfonatos/farmacologia , Imidazóis/farmacologia , Ácido Mevalônico/metabolismo , Neoplasias da Próstata/tratamento farmacológico , Receptores de Antígenos de Linfócitos T gama-delta/imunologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Linhagem Celular Tumoral , Colesterol/metabolismo , Citotoxicidade Imunológica/efeitos dos fármacos , Humanos , Masculino , Neoplasias da Próstata/imunologia , Neoplasias da Próstata/metabolismo , Transdução de Sinais/efeitos dos fármacos , Regulação para Cima/efeitos dos fármacos , Ácido ZoledrônicoRESUMO
Several pre-clinical and clinical studies have demonstrated zoledronic acid (Zol), which regulates the mevalonate pathway, has efficient anti-cancer effects. Zol can also induce autophagy. The aim of this study is to add new understanding to the mechanism of autophagy induction by Zol. LC3B-II, the marker for autophagy was increased by Zol treatment in breast cancer cells. Autophagosomes induced by Zol were visualized and quantified in both transient (pDendra2-hLC3) and stable MCF-7-GFP-LC3 cell lines. Acidic vesicular organelles were quantified using acridine orange. Zol induced a dose and time dependent autophagy. Treatment of Zol increased oxidative stress in MCF-7 cells, which was reversed by GGOH or anti-oxidants. On the other hand, treatment with GGOH or anti-oxidants resulted in decreased levels of LC3B-II. Further, the induced autophagy was irreversible, as the washout of Zol after 2 h or 24 h resulted in similar levels of autophagy, as induced by continuous treatment after 72 h. Thus, it can be summarized that Zol can induce a dose dependent but irreversible autophagy, by its effect on the mevalonate pathway and oxidative stress. This study adds to the understanding of the mechanism of action of Zol, and that it can induce autophagy at clinically relevant shorter exposure times in cancer cells.
Assuntos
Autofagia/efeitos dos fármacos , Conservadores da Densidade Óssea/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Difosfonatos/uso terapêutico , Imidazóis/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Conservadores da Densidade Óssea/farmacologia , Neoplasias da Mama/metabolismo , Difosfonatos/farmacologia , Humanos , Imidazóis/farmacologia , Células MCF-7 , Ácido Mevalônico/metabolismo , Ácido ZoledrônicoRESUMO
Bisphosphonates are a class of drugs developed over the past three decades for the treatment of metabolic bone diseases with high bone turnover, such as Paget's disease, tumor associated osteolysis and osteoporosis. The exceptional pharmacokinetic profile of bisphosphonates makes them very suitable and safe drugs for the treatment of bone diseases, because, by conventional administration, osseous tissue and bone resorbing osteoclasts are the targets for these drugs as a result of the very high affinity of bisphosphonates for bone mineral. Several recent studies have demonstrated, however, that bisphosphonates decrease tumor burden in bone in rodent models of myeloma and metastatic bone disease, with suggestions of antitumor effects also in patients. Although decreased tumor burden could be a consequence of inhibition of bone resorption, there is increasing evidence that bisphosphonates might also have direct effects on tumor cell in vivo, since effects on tumors outside of skeleton or at doses not inhibiting bone resorption have been reported. Recent studies also suggest that bisphosphonates have inhibitory effect also on endothelial cell function and angiogenesis in tumor tissue. These findings suggest that the target cells for bisphosphonates as well as their molecular mechanism of action may be more diverse and complex than realized so far. This review highlights the main methodologies used to monitor the action of BPs in vitro cell models, with a special emphasis on the detection of BP-induced ATP-analoques by mass spectrometry. In addition, cell death monitoring, immunomodulatory effects and inhibition of growth/proliferation are described.
Assuntos
Conservadores da Densidade Óssea/metabolismo , Conservadores da Densidade Óssea/farmacologia , Difosfonatos/metabolismo , Difosfonatos/farmacologia , Células Endoteliais/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , Neoplasias/tratamento farmacológico , Trifosfato de Adenosina/análogos & derivados , Animais , Apoptose/efeitos dos fármacos , Conservadores da Densidade Óssea/química , Linhagem Celular , Linhagem Celular Transformada , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Difosfonatos/química , Desenho de Fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Células Endoteliais/metabolismo , Humanos , Fatores Imunológicos/química , Fatores Imunológicos/metabolismo , Fatores Imunológicos/farmacologia , Macrófagos/metabolismo , Neoplasias/metabolismo , Neovascularização Patológica/tratamento farmacológico , Neovascularização Patológica/metabolismo , Compostos Organofosforados/química , Compostos Organofosforados/metabolismoRESUMO
BACKGROUND: Easily applicable water-specific instruments measuring local oedema in skin are not available. The aim of this study is to demonstrate quantitative assessment of skin oedema with the dielectric technique by measuring increase of skin water content related to sodium lauryl sulphate (SLS)-induced irritant contact dermatitis. METHODS: Irritant skin reaction and resulting oedema were induced by an irritant patch test on volar forearms in 12 healthy volunteers with the application of 1% SLS for 6 h. After occlusion the volunteers were divided into two groups: the patch test site of group I (six volunteers) received no treatment other than a base cream for the skin reaction, while for group II (six volunteers) a strong corticosteroid (clobetasol propionate) was applied on the irritant skin. During a follow-up of 72 h, erythema was scored visually, and irritant-induced oedema was measured with a novel water-specific instrument MoistureMeter-D. RESULTS: In the untreated irritant skin, a maximum increase of 45% in skin water content was found at 10 h postocclusion and water content was still elevated at 72 h. With these persons, the degree of oedema agreed well with the ultrasound-measured skin thickness (P=0.053). In the corticosteroid-treated skin, an increase of 8% in water content was measured during 72 h but there was no correlation between oedema and skin thickness. There was no correlation between erythema and oedema in untreated or corticosteroid-treated skin. CONCLUSION: The new instrument can easily be applied for noninvasive quantitative evaluation of local oedema and fluid retention in irritant-exposed skin.
Assuntos
Água Corporal/metabolismo , Dermatite Irritante/metabolismo , Edema/diagnóstico , Eletroquímica/métodos , Dermatopatias/diagnóstico , Pele/metabolismo , Adulto , Anti-Inflamatórios/uso terapêutico , Clobetasol/uso terapêutico , Dermatite Irritante/complicações , Dermatite Irritante/tratamento farmacológico , Edema/diagnóstico por imagem , Eritema/etiologia , Eritema/patologia , Humanos , Pele/diagnóstico por imagem , Pele/efeitos dos fármacos , Dermatopatias/diagnóstico por imagem , Dodecilsulfato de Sódio , Tensoativos , UltrassonografiaRESUMO
OBJECTIVE: High-dose liposomal bisphosphonates exert apoptotic effects. This work studies the chondroprotective and anti-inflammatory properties of intra-articularly administered low-dose, non-cytotoxic liposomal clodronate. METHODS: Antigen induced arthritis in rabbits was treated with intra-articular injections of liposomal clodronate. Drug effects on cartilage oligomeric matrix protein COMP was assessed using immunohistochemistry and morphometry of synovial membrane and hyaline articular cartilage. RESULTS: COMP remained close to normal in liposomal clodronate treated superficial articular cartilage compared to a significant loss of COMP in arthritis controls treated with empty liposomes. The middle and deep layers of the hyaline articular cartilage were characterized by highly increased COMP expression in liposomal clodronate treated AIA joints compared to controls. In contrast to cartilage, synovial COMP expression was slightly decreased as a result of liposomal clodronate treatment. CONCLUSION: Low-dose, non-cytotoxic liposomal clodronate exerts a dichotomous effect on synovial membrane and articular cartilage COMP in the AIA model. COMP is a useful inflammation marker in the synovial tissue, but it also contributes to the structural integrity of the hyaline articular cartilage forming bridges between type II and IX collagens. Enhancement of COMP in clodronate treated AIA cartilage suggests a chondroprotective and anti-inflammatory effect in the inflammatorily damaged and mechanically strained cartilage.
Assuntos
Artrite Experimental/tratamento farmacológico , Conservadores da Densidade Óssea/administração & dosagem , Cartilagem Articular/efeitos dos fármacos , Ácido Clodrônico/administração & dosagem , Modelos Animais de Doenças , Proteínas da Matriz Extracelular/metabolismo , Glicoproteínas/metabolismo , Animais , Artrite Experimental/etiologia , Artrite Experimental/metabolismo , Conservadores da Densidade Óssea/farmacologia , Cartilagem Articular/metabolismo , Cartilagem Articular/patologia , Ácido Clodrônico/farmacologia , Proteínas da Matriz Extracelular/imunologia , Glicoproteínas/imunologia , Imunoglobulina G/imunologia , Injeções Intra-Articulares , Lipossomos , Proteínas Matrilinas , Coelhos , Membrana Sinovial/efeitos dos fármacos , Membrana Sinovial/metabolismo , Membrana Sinovial/patologiaRESUMO
Metalloproteinases (MMP), particularly MMP-9 produced by the intratumor monocyte/macrophages, play an important role in tumor invasion and metastases. Recent clinical trials in patients with primary breast cancer suggest that bisphosphonates (BP), above all clodronate, may reduce bone metastases. The aim of the present study was to evaluate whether the effects of BPs on cancer dissemination include inhibition of MMP-9 production in human monocyte/macrophages. The effects of clodronate and pamidronate on the MMP-9 expression in and secretion from stimulated human monocyte/macrophages were measured using quantitative reverse transcriptase - polymerase chain reaction (RT-PCR) and enzyme-linked immunoadsorbent assay (ELISA), respectively. The MMP-9 mRNA levels remained relatively stable in the presence of clodronate. In contrast, pamidronate at 30 microM-300 microM increased the mRNA levels 5- to 10-fold. MMP-9 secretion was dose-dependently down-regulated by clodronate whereas pamidronate at 30 microM induced a 50% increase on MMP-9 secretion (p < 0.05), followed by a down-regulation at higher concentrations. The results suggest that MMP-9 is differentially regulated at mRNA and enzyme protein level by BPs, which affect ATP-dependent intracellular enzymes (clodronate) or post-translational modification of GTPases (pamidronate). These findings may have implications for the therapeutic use of these compounds.
Assuntos
Ácido Clodrônico/farmacologia , Difosfonatos/farmacologia , Macrófagos/efeitos dos fármacos , Metaloproteinase 9 da Matriz/biossíntese , Monócitos/efeitos dos fármacos , Meios de Cultivo Condicionados , Relação Dose-Resposta a Droga , Regulação para Baixo , Ativação Enzimática/efeitos dos fármacos , Ensaio de Imunoadsorção Enzimática , Humanos , Técnicas In Vitro , Macrófagos/enzimologia , Monócitos/enzimologia , Pamidronato , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
Etidronate and clodronate are bisphosphonates that inhibit the development of experimental atherosclerosis. Etidronate decreases the intimamedia thickness of carotid artery even in man. Liposome-encapsulated bisphosphonates inhibit the cellular metabolism of atherogenic, modified low-density lipoprotein (acetyl-LDL) by cultured macrophages. In the present study, the effects of new bisphosphonate tiludronate and nitrogen-containing bisphosphonate alendronate on cell viability and cellular uptake and degradation of acetyl-LDL were investigated in vitro with macrophages and arterial smooth muscle cells, which have a significant role in atherogenesis. Tiludronate and alendronate decreased the viability of RAW 264 macrophages at high concentration (1,000 microM; p < 0.05), while liposome-encapsulated drugs suppressed the viability at concentrations of 30-300 microM. At concentrations greater than or equal to 10 microM, tiludronate and alendronate inhibited the uptake and degradation of acetyl-LDL by RAW 264 cells in a concentration-dependent manner (p < 0.001). None of the bisphosphonates affected the viability of smooth muscle cells, and none but alendronate at a high concentration (1,000 microM) inhibited the uptake and degradation of acetyl-LDL by smooth muscle cells. The results show that tiludronate and alendronate inhibit the atherogenic activity of macrophages in vitro, as shown previously with etidronate and clodronate, providing further evidence for the antiatherogenic effects of bisphosphonates.
Assuntos
Difosfonatos/farmacologia , Inibidores do Crescimento/farmacologia , Lipoproteínas LDL/metabolismo , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/metabolismo , Animais , Aorta/citologia , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Portadores de Fármacos/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Humanos , Lipossomos/farmacologia , Macrófagos/citologia , Camundongos , Músculo Liso Vascular/citologia , Músculo Liso Vascular/fisiologia , Fagocitose/efeitos dos fármacos , Fagocitose/fisiologia , CoelhosRESUMO
The nitrogen-containing bisphosphonate alendronate inhibits osteoclast-mediated bone resorption through inhibition of the mevalonate pathway. This results in impaired protein prenylation and may affect the function of small GTPases in osteoclasts. Since these proteins are important regulators of vesicle transport in cells, we investigated the possible interference of alendronate with these processes in isolated rat osteoclasts. We show here that alendronate-induced inhibition of bone resorption coincides with accumulation of tartrate-resistant acid phosphatase- and electron dense material-containing tubular vesicles in osteoclasts. Alendronate-induced changes in osteoclasts also included widening of the sealing zone areas and incomplete organization of tight attachments and ruffled borders. Osteoclasts also appeared partially detached from the bone surface, and organic matrix was typically dissolved only at the edges of the resorption pits on alendronate-coated bone slices. In contrast, resorption pits on the control and clodronate-coated bone slices were thoroughly resorbed. Inhibition of bone resorption by alendronate was not, however, related to a decrease in osteoclast number. In conclusion, our findings suggest that alendronate inactivates osteoclasts by mechanisms that impair their intracellular vesicle transport, apoptosis being only a secondary phenomenon to this.
Assuntos
Alendronato/farmacologia , Reabsorção Óssea/induzido quimicamente , Osso e Ossos/efeitos dos fármacos , Osteoclastos/efeitos dos fármacos , Vesículas Transportadoras/efeitos dos fármacos , Fosfatase Ácida/metabolismo , Alendronato/administração & dosagem , Animais , Animais Recém-Nascidos , Apoptose/efeitos dos fármacos , Transporte Biológico/efeitos dos fármacos , Reabsorção Óssea/patologia , Osso e Ossos/citologia , Bovinos , Técnicas In Vitro , Isoenzimas/metabolismo , Lipossomos , Osteoclastos/ultraestrutura , Ratos , Ratos Sprague-Dawley , Fosfatase Ácida Resistente a Tartarato , Vesículas Transportadoras/metabolismo , Vesículas Transportadoras/ultraestruturaRESUMO
OBJECTIVE: The primary aims of this study were to determine whether clodronate and liposome-encapsulated clodronate are metabolized to adenosine 5'-(beta,gamma-dichloromethylene) triphosphate (AppCCl2p) by osteoclasts and macrophages in vivo, and to determine whether intracellular accumulation of this metabolite accounts for the antiresorptive and antimacrophage effects of clodronate. To compare the mechanism of action of clodronate and alendronate, effects on protein prenylation in osteoclasts and macrophages in vivo were also assessed. METHODS: High-performance liquid chroma-tography-mass spectrometry was used to determine whether rabbit osteoclasts (purified ex vivo with immunomagnetic beads) metabolize clodronate, and whether rat peritoneal macrophages metabolize liposome-encapsulated clodronate, following in vivo administration. The effects of clodronate and AppCCl2p on bone resorption, osteoclast number, and apoptosis in vitro were compared. Using an antibody to the unprenylated form of RaplA, effects on protein prenylation were assessed by Western blot analysis of osteoclast and peritoneal macrophage lysates from bisphosphonate-treated animals. RESULTS: AppCCl2p could be detected in extracts from osteoclasts purified from clodronate-treated rabbits. Intracellular accumulation of AppCCl2p caused a reduction in the number of osteoclasts, increased osteoclast apoptosis, and inhibited bone resorption in vitro. These effects were indistinguishable from those of clodronate. Liposome-encapsulated clodronate was also metabolized to AppCCl2p by rat peritoneal macrophages in vivo. Liposome-encapsulated clodronate caused an increase in peritoneal macrophage apoptosis in ex vivo cultures that was indistinguishable from the increase in apoptosis caused by liposome-encapsulated AppCCl2p. Unlike alendronate, clodronate and its metabolite did not affect prenylation of the small GTPase RaplA in osteoclasts or macrophages in vivo. CONCLUSION: These results provide the first direct evidence that the antiinflammatory and antiresorptive effects of clodronate on macrophages and osteoclasts in vivo occur via the intracellular formation of AppCCl2p.
Assuntos
Anti-Inflamatórios/farmacocinética , Reabsorção Óssea/tratamento farmacológico , Ácido Clodrônico/farmacocinética , Macrófagos Peritoneais/efeitos dos fármacos , Osteoclastos/efeitos dos fármacos , Trifosfato de Adenosina/análogos & derivados , Trifosfato de Adenosina/metabolismo , Alendronato/farmacocinética , Analgésicos não Narcóticos/farmacocinética , Animais , Apoptose/efeitos dos fármacos , Reabsorção Óssea/patologia , Cápsulas , Células Cultivadas , Lipossomos , Macrófagos Peritoneais/citologia , Osteoclastos/citologia , Prenilação de Proteína , Coelhos , Ratos , Ratos Sprague-Dawley , Proteínas rap1 de Ligação ao GTP/metabolismoRESUMO
Bisphosphonates have become an important addition to the pharmacological armamentarium against postmenopausal osteoporosis. One of the major side effects of oral therapy with some nitrogen-containing bisphosphonates appears to be gastrointestinal (GI) intolerability, particularly esophageal irritation and ulceration. Because nitrogen-containing bisphosphonates can cause apoptosis in a variety of cell types in vitro, by inhibiting the mevalonate pathway, we hypothesized that the effect of these agents on the GI tract may be due to apoptosis or inhibition of growth of gut epithelial cells. A comparison between clodronate, etidronate, pamidronate, alendronate, and risedronate demonstrated that only the nitrogen-containing bisphosphonates were effective at inducing apoptosis or inhibiting proliferation of Caco-2 human epithelial cells in vitro, at concentrations of between 10 and 1000 micromol/L. The ability of nitrogen-containing bisphosphonates to cause apoptosis and inhibit Caco-2 cell proliferation was due to inhibition of the mevalonate pathway, because the addition of farnesol, oxidized low-density lipoprotein (LDL) cholesterol, or especially geranylgeraniol suppressed the effects. Furthermore, pamidronate, alendronate, and risedronate inhibited protein prenylation in Caco-2 cells, as determined by analysis of the processing of Rap1A, a prenylated small GTPase. These studies suggest that the effects of nitrogen-containing bisphosphonates observed in the GI tract may be due to inhibition of proliferation or apoptosis of gut epithelial cells, following loss of prenylated proteins and sterols.
Assuntos
Apoptose/efeitos dos fármacos , Apoptose/fisiologia , Difosfonatos/toxicidade , Ácido Mevalônico/metabolismo , Compostos de Nitrogênio/toxicidade , Células CACO-2 , Divisão Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Diterpenos/farmacologia , Células Epiteliais/citologia , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Gastroenteropatias/induzido quimicamente , Humanos , Marcação In Situ das Extremidades Cortadas , Técnicas In Vitro , Prenilação de Proteína , Proteínas rap1 de Ligação ao GTP/metabolismoRESUMO
OBJECTIVE: To assess the clinical and histologic effects of an intraarticular application of low-dose (non-cytotoxic) liposomal clodronate in established antigen-induced monarthritis (AIA) in rabbits. METHODS: AIA was monitored by assessments of joint swelling, C-reactive protein levels, and radiographic changes in 17 NZW rabbits for 8 weeks during the course of weekly intraarticular injections of liposomal clodronate (0.145 mg/injection, low dose) or "empty" liposomes. The contralateral knee was injected with liposome buffer alone as the control. End-point analyses included macroscopic joint examination, immuno- and TUNEL staining, Safranin O staining/microspectrophotometry, and tumor necrosis factor alpha (TNFalpha) convertase enzyme (TACE) inhibition assay. RESULTS: Liposomal clodronate-treated rabbits showed a reduction and delay in joint swelling during the first 3 injections. Expression of matrix-bound (solubilized) TNFalpha, lining cell hyperplasia, and levels of RAM-11+ macrophages were low in the synovium of the liposomal clodronate treatment group, but the proportion of apoptotic lining cells was not affected. The radiologic score was low at the end of weeks 2 and 4, but at 8 weeks, no difference, compared with controls, was found in pannus formation or in the extent of joint erosion; also, joint swelling was higher than before initiation of treatment. Injections of liposomal clodronate prevented cartilage proteoglycan loss, which was significant in the superficial zone only. TACE activity was not inhibited by clodronate. CONCLUSION: Liposomal clodronate had temporary antiinflammatory and antierosive effects on established AIA in rabbits. Over the long-term, the loss of cartilage proteoglycans was halted. This observed treatment effect may be related to the inhibition of TNFalpha production and processing in the synovium.
Assuntos
Artrite/tratamento farmacológico , Ácido Clodrônico/farmacologia , Proteoglicanas/metabolismo , Proteínas ADAM , Proteína ADAM17 , Animais , Antígenos , Apoptose , Artrite/etiologia , Artrite/metabolismo , Artrite/patologia , Peso Corporal/efeitos dos fármacos , Proteína C-Reativa/metabolismo , Cartilagem/efeitos dos fármacos , Cartilagem/metabolismo , Ácido Clodrônico/administração & dosagem , Injeções Intra-Articulares , Lipossomos , Metaloendopeptidases/antagonistas & inibidores , Microespectrofotometria , Fenazinas/química , Coelhos , Membrana Sinovial/metabolismo , Membrana Sinovial/patologiaRESUMO
Clodronate, like other bisphosphonates, is poorly absorbed from the gastrointestinal tract, mainly due to its high hydrophilicity and ability to form complexes with divalent cations in the gastrointestinal tract. One strategy for improving oral absorption of these types of molecules is to develop more lipophilic derivatives. The importance of lipophilicity and calcium chelation in the absorption of clodronate was evaluated by studying the penetration of clodronate and its mono-, di-, and triphenyl esters through human intestinal Caco-2 cells. The transport rates of [(14)C]-clodronate and its mono-, di-, and triphenyl esters were quantified by calculating their apparent permeability coefficients (P(app)) both in normal (1.3 mM) calcium concentration and in 'minimum-calcium model'. The transport rate of 1 mM clodronate was very low (0.25 x 10(-7) cm/s), while the removal of calcium from the apical side increased this transport rate 6-fold. The transport rate of clodronate was increased with increasing dose. Mono- and diphenyl esters did not significantly enhance the transport of clodronate. Triphenyl ester, however, increased the transport rate 17-fold compared with parent clodronate. Removal of calcium did not affect the transport rates of di- or triphenyl esters, which indicated that the esterification of hydroxyl groups of clodronate decreased calcium complex formation. These results indicate that clodronate is transported paracellularly through Caco-2 cells and that calcium decreases strongly its absorption. They further suggest that at least three phosphate hydroxyl groups need to be substituted until the permeation route is changed from paracellular to transcellular.
Assuntos
Analgésicos não Narcóticos/farmacocinética , Cálcio/farmacologia , Ácido Clodrônico/análogos & derivados , Ácido Clodrônico/farmacocinética , Analgésicos não Narcóticos/química , Transporte Biológico Ativo/efeitos dos fármacos , Células CACO-2 , Fenômenos Químicos , Físico-Química , Ácido Clodrônico/química , Humanos , Absorção Intestinal , Lipídeos/química , Peso Molecular , Sais de Tetrazólio , TiazóisRESUMO
PURPOSE: Non-nitrogen-containing bisphosphonates, such as clodronate (dichloromethylene bisphosphonate), appear to act as prodrugs, their active form being the AppCp-type analogues of ATP. To further elucidate this, we examined the cellular uptake of clodronate and intracellular accumulation of the metabolite of clodronate (AppCCl2p) in RAW 264 macrophages, the influence of clodronate metabolism on the intracellular ATP concentration, and the time course of clodronate metabolism and the effects of clodronate on cytokine secretion from macrophages. METHODS: The cellular uptake of clodronate was measured using 14C-labeled clodronate. AppCCl2p was determined in cell extracts by using an ion-pairing HPLC-ESI-MS. The cytokine concentrations in the culture supernatants were measured with time-resolved fluoroimmunoassay. Intracellular ATP concentration was measured with a luminometer using a luciferin-luciferase assay. RESULTS: Of the clodronate internalized by macrophages in vitro, 30-55% is metabolized to AppCCl2p, which accumulates to high intracellular concentrations during the first 12 h of exposure. This accumulation does not affect the ATP levels in the cells. The time course of metabolite appearance in the cells and the inhibition of cytokine secretion were very similar. CONCLUSIONS: These results strongly support the idea that clodronate acts as a prodrug, the active form being its intracellular AppCCl2p metabolite.
Assuntos
Analgésicos não Narcóticos/metabolismo , Ácido Clodrônico/metabolismo , Macrófagos/metabolismo , Trifosfato de Adenosina/metabolismo , Analgésicos não Narcóticos/farmacologia , Animais , Biotransformação , Linhagem Celular , Ácido Clodrônico/farmacologia , Citocinas/metabolismo , Composição de Medicamentos , Cinética , Lipossomos , Macrófagos/efeitos dos fármacos , CamundongosRESUMO
BACKGROUND: Osteoclasts secrete tartrate-resistant acid phosphatase (TRAP; EC 3.1.3.2) 5b into the circulation. We studied the release of TRAP 5b from osteoclasts using a mouse in vitro osteoclast differentiation assay. METHODS: We developed and characterized a polyclonal antiserum in rabbits, using purified human osteoclastic TRAP 5b as antigen. The antiserum was specific for TRAP in Western analysis of mouse osteoclast culture medium and was used to develop an immunoassay. We cultured mouse bone marrow-derived osteoclast precursor cells for 3-7 days with or without clodronate in the presence of vitamin D and analyzed the number of osteoclasts formed and the amount of TRAP 5b activity released into the culture medium. RESULTS: TRAP 5b activity was not secreted from osteoclast precursor cells. Addition of clodronate-containing liposomes decreased in a dose-dependent manner the number of osteoclasts and TRAP 5b activity released in 6-day cultures. The amount of TRAP 5b activity in the medium detected by the immunoassay correlated significantly with the number of osteoclasts formed (r = 0.94; P<0.0001; n = 120). CONCLUSIONS: The TRAP 5b immunoassay can be used to replace the laborious and time-consuming microscopic counting of osteoclasts in the osteoclast differentiation assay and to test the effects of potential therapeutic agents on osteoclast differentiation, enabling fast screening of large amounts of potential therapeutic agents.
Assuntos
Fosfatase Ácida/metabolismo , Isoenzimas/metabolismo , Osteoclastos/metabolismo , Fosfatase Ácida/imunologia , Animais , Células da Medula Óssea/citologia , Células da Medula Óssea/enzimologia , Células da Medula Óssea/metabolismo , Diferenciação Celular , Células Cultivadas , Humanos , Soros Imunes , Imunoensaio , Isoenzimas/imunologia , Camundongos , Osteoclastos/citologia , Osteoclastos/enzimologia , Coelhos , Fosfatase Ácida Resistente a TartaratoRESUMO
This work was aimed at improving the absorption of bisphosphonates by targeting carrier systems in the intestine and the intestinal peptide carrier system (hPEPT1), in particular. (14)C-Labeled pamidronate and alendronate as well as radiolabeled and "cold" peptidyl-bisphosphonates, Pro-[(3)H]Phe-[(14)C]pamidronate, and Pro-[(3)H]Phe-[(14)C]alendronate were synthesized. In situ single-pass perfusion studies revealed competitive inhibition of transport by Pro-Phe, suggesting peptide carrier-mediated transport. Prodrug transport in the Caco-2 cell line was significantly better than that of the parent drugs, and the prodrugs exhibited high affinity to the intestinal tissue. Oral administration of the dipeptidyl prodrugs resulted in a 3-fold increase in drug absorption following oral administration in rats, and the bioavailability of Pro-Phe-alendronate was 3.3 (F(TIBIA)) and 1.9 (F(URINE)) times higher than that of the parent drug. The results indicate that the oral absorption of bisphosphonates can be improved by peptidyl prodrugs via the hPEPT1; however, other transporters may also be involved.
Assuntos
Alendronato/administração & dosagem , Alendronato/síntese química , Dipeptídeos/síntese química , Difosfonatos/administração & dosagem , Difosfonatos/síntese química , Pró-Fármacos/síntese química , Simportadores , Administração Oral , Alendronato/análogos & derivados , Alendronato/química , Alendronato/farmacocinética , Animais , Disponibilidade Biológica , Células CACO-2 , Proteínas de Transporte/metabolismo , Precipitação Química , Dipeptídeos/química , Dipeptídeos/farmacocinética , Difosfonatos/química , Difosfonatos/farmacocinética , Durapatita/química , Humanos , Injeções Intravenosas , Absorção Intestinal , Pamidronato , Transportador 1 de Peptídeos , Pró-Fármacos/química , Pró-Fármacos/farmacocinética , Ratos , Distribuição TecidualRESUMO
The aim of this study was to determine if transdermal penetration of levosimendan, a novel positive inotropic drug, could be enhanced and controlled by formulation modifications. Penetration of levosimendan across human epidermis in vitro was determined using abdominal excised skin and diffusion cells. Predicted steady-state plasma concentrations of levosimendan were estimated using permeabilities and pharmacokinetic parameters of levosimendan. For penetration enhancement we used different pH values, co-solvents, cyclodextrins, surfactants, penetration enhancers, liposomes, and iontophoresis. Sodium lauryl sulfate, ethanol, oleic acid, and soya phosphatidylcholine or their combinations clearly increased levosimendan permeation across the skin in vitro. Iontophoresis was also an efficient method to increase transdermal permeation of levosimendan. A hydrophilic co-solvent/penetration enhancer is needed to achieve better permeability of levosimendan across the skin. In conclusion, transdermal delivery of levosimendan can be significantly increased by formulation modification. Based on kinetic calculations, therapeutic plasma concentrations may be achievable transdermally.
Assuntos
Cardiotônicos/farmacocinética , Hidrazonas/farmacocinética , Piridazinas/farmacocinética , Absorção Cutânea/efeitos dos fármacos , Administração Cutânea , Cardiotônicos/química , Química Farmacêutica , Humanos , Hidrazonas/química , Concentração de Íons de Hidrogênio , Piridazinas/química , Simendana , Absorção Cutânea/fisiologia , Tensoativos/farmacocinéticaRESUMO
BACKGROUND: Bisphosphonates currently are the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor-associated osteolysis and hypercalcemia, Paget's disease, and osteoporosis. These compounds have high affinity for calcium and therefore target to bone mineral, where they appear to be internalized selectively by bone-resorbing osteoclasts and inhibit osteoclast function. METHODS: This article reviews the pharmacology of bisphosphonates and the relation between the chemical structure of bisphosphonates and antiresorptive potency, and describes recent new discoveries of their molecular mechanisms of action in osteoclasts. RESULTS: Bisphosphonates can be grouped into two pharmacologic classes with distinct molecular mechanisms of action. Nitrogen-containing bisphosphonates (the most potent class) act by inhibiting the mevalonate pathway in osteoclasts, thereby preventing prenylation of small GTPase signaling proteins required for osteoclast function. Bisphosphonates that lack a nitrogen in the chemical structure do not inhibit protein prenylation and have a different mode of action that may involve the formation of cytotoxic metabolites in osteoclasts or inhibition of protein tyrosine phosphatases. CONCLUSIONS: Bisphosphonates are highly effective inhibitors of bone resorption that selectively affect osteoclasts. After more than 30 years of clinical use, their molecular mechanisms of action are only just becoming clear.
Assuntos
Difosfonatos/farmacologia , Animais , Reabsorção Óssea/tratamento farmacológico , Osso e Ossos/efeitos dos fármacos , Difosfonatos/farmacocinética , Humanos , Osteoblastos/efeitos dos fármacos , Osteoclastos/efeitos dos fármacos , Prenilação de Proteína/efeitos dos fármacos , Proteínas Tirosina Fosfatases/antagonistas & inibidores , ATPases Translocadoras de Prótons/antagonistas & inibidores , Relação Estrutura-AtividadeRESUMO
Anti-sense oligonucleotides are potential therapeutic agents that are used to block protein expression from mRNA. To assess the essential properties for an efficient cellular delivery system of phosphorothioate oligonucleotides (PS-ODNs), different cationic carriers were compared. The carriers were complexed with oligonucleotides at various +/- charge ratios in MES-Hepes buffer. Cationic polymers, polylysines (PLL, mean MWs 4000, 20000, 200000 kDa), polyethyleneimines (PEI, mean MWs 25 and 800 kDa) and fractured sixth-generation polyamidoamine dendrimer (PAMAM) were tested for ODN delivery into a D 407 cell line (human retinal pigment epithelial cells) with stably transfected luciferase gene. Anti-sense ODN was directed against the luciferase gene, and the anti-sense effect was determined using a luminometric method. Lipid-based vehicles included DOTAP, DOTAP/DOPE (1/1 by mol), DOTAP/Chol (1/1 by mol), DOTAP/DOPE/Chol (2/1/1 by mol), DOGS and Cytofectin GS/DOPE (2/1 by mol). Additionally a membrane-active peptide JTS-1 (NH(2) -GLFEALLELLESLWELLLEA-COOH) was added to the complexes containing DOTAP, PEI or PLL. In D 407 and CV-1 cells, the anti-sense effect was seen only with lipid-based carriers with a membrane-active component (DOPE or JTS-1). The polymeric systems were ineffective. The effect of the complexation medium was further studied on CV-1 cells. Complexes were prepared in either water, MES-Hepes buffer or cell growth medium (DMEM). Complexes prepared in water were generally most effective and the greater activity is probably due to the smaller complex size. Complex sizes differed greatly in buffer and DMEM, especially in the case of DOPE containing complexes. In conclusion, lipid carrier with a membrane active component and small complex size are required for an efficient cellular delivery of phosphorothioate oligonucleotides.
Assuntos
Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos Antissenso/farmacocinética , Compostos Organotiofosforados/administração & dosagem , Linhagem Celular , Portadores de Fármacos , Humanos , Lipídeos/química , Lipossomos , Luciferases/genética , Luciferases/metabolismo , Oligonucleotídeos Antissenso/síntese química , Compostos Organotiofosforados/química , Compostos Organotiofosforados/farmacocinética , Tamanho da Partícula , Transfecção/genética , Transfecção/métodosRESUMO
The aim of the present study was to evaluate the influence of the lipids EPC (L-alpha-phosphatidylcholine, egg lecithin), DSPC (distearoylphosphatidylcholine), and SA (stearylamine) on the iontophoretic mannitol transport through human skin in vitro. The skin was pretreated with 1 mM lipid suspension with ethanol (32%) for 24 h prior to the iontophoretic experiment with mannitol. In addition, the penetration of fluorescent lipids into the epidermis during the pretreatment was studied by confocal laser scanning microscopy (CLSM). The results of the present study show that pretreatment of the skin with zwitterionic EPC increases the iontophoretic transdermal mannitol flux about three-fold compared to iontophoretic control without pretreatment. However, skin pretreatment with another zwitterionic phospholipid, DSPC, did not influence the iontophoretic flux of mannitol. In contrast, pretreatment of the skin with cationic SA decreased the iontophoretic mannitol flow from the anode. It is concluded that EPC works as a penetration enhancer further increasing the transdermal mannitol flux during iontophoresis. In contrast, the cationic stearylamine changes the charge of the skin, thus leading to decreased electroosmosis and decreased mannitol flux. Hence, the effects of stearylamine are assumed to be mediated by the alterations in the charge of the stratum corneum structures, while EPC is suggested to decrease the permeability barrier of the skin.
Assuntos
Lipídeos/farmacologia , Manitol/farmacocinética , Absorção Cutânea/efeitos dos fármacos , Administração Cutânea , Difusão , Eletrodos , Humanos , Técnicas In Vitro , Iontoforese , Manitol/administração & dosagem , Microscopia Confocal , Fosfatidilcolinas/farmacologiaRESUMO
Clodronate belongs to the family of bisphosphonates, which are synthetic analogues of pyrophosphate. Bisphosphonates are widely used in the treatment of metabolic bone diseases. Some bisphosphonates, including clodronate, can be metabolized in cells into non-hydrolysable nucleotide analogues. In this paper, we describe a new method for extraction and quantitation of the clodronate metabolite in cell lysates by using ion-pairing HPLC method that is compatible with negative ion electrospray ionization mass spectrometry (ESI-MS). The method was used for detection of the metabolite of clodronate in extracts from RAW 264 macrophage cells after treatment with clodronate.